^“Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution”. Prostaglandins Leukot. Essent. Fatty Acids73 (3–4): 141–62. (2005). doi:10.1016/j.plefa.2005.05.002. PMID16005201.
^“Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2”. J. Biol. Chem.271 (52): 33157–60. (December 1996). doi:10.1074/jbc.271.52.33157. PMID8969167.
^“A mechanistic study of self-inactivation of the peroxidase activity in prostaglandin H synthase-1”. J. Biol. Chem.274 (14): 9231–7. (April 1999). doi:10.1074/jbc.274.14.9231. PMID10092596.
^“The kinetic factors that determine the affinity and selectivity for slow binding inhibition of human prostaglandin H synthase 1 and 2 by indomethacin and flurbiprofen”. J. Biol. Chem.271 (7): 3548–54. (February 1996). doi:10.1074/jbc.271.7.3548. PMID8631960.
^“Mechanisms for the autoxidation of polyunsaturated lipids”. Accounts of Chemical Research19 (9): 262–8. (1986). doi:10.1021/ar00129a001.
^“A carbon-centered free radical intermediate in the prostaglandin synthetase oxidation of arachidonic acid. Spin trapping and oxygen uptake studies”. J. Biol. Chem.255 (11): 5019–22. (June 1980). doi:10.1016/S0021-9258(19)70741-8. PMID6246094.
^“Analysis of hydroperoxide-induced tyrosyl radicals and lipoxygenase activity in aspirin-treated human prostaglandin H synthase-2”. Biochemistry36 (7): 1836–45. (February 1997). doi:10.1021/bi962476u. PMID9048568.
^“Enzymatic conversions of 10,10-difluoroarachidonic acid with PGH synthase and soybean lipoxygenase”. Journal of the American Chemical Society109 (12): 3692–3698. (June 1987). doi:10.1021/ja00246a028.
^Tikhonovich, Marina V.; Erdiakov, Aleksei K.; Gavrilova, Svetlana A. (2017-06-21). “Nonsteroid anti-inflammatory therapy suppresses the development of proliferative vitreoretinopathy more effectively than a steroid one” (英語). International Ophthalmology38 (4): 1365–1378. doi:10.1007/s10792-017-0594-3. ISSN0165-5701. PMID28639085.
^“A new cyclo-oxygenase-2 gene variant in the Han Chinese population is associated with an increased risk of gastric carcinoma”. Mol Diagn Ther14 (6): 351–5. (December 2010). doi:10.1007/bf03256392. PMID21275453.
^“Colocalization and interaction of cyclooxygenase-2 with caveolin-1 in human fibroblasts”. J. Biol. Chem.276 (37): 34975–82. (September 2001). doi:10.1074/jbc.M105946200. PMID11432874.
“Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells”. J. Steroid Biochem. Mol. Biol.80 (2): 203–12. (February 2002). doi:10.1016/S0960-0760(01)00187-X. PMID11897504.
“Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers”. Prostaglandins Leukot. Essent. Fatty Acids66 (1): 13–8. (January 2002). doi:10.1054/plef.2001.0335. PMID12051953.
“Cox and mesothelioma: an overview”. Histol. Histopathol.20 (4): 1267–74. (October 2005). PMID16136507.
“Relationship between aromatase and cyclooxygenases in breast cancer: potential for new therapeutic approaches”. Minerva Endocrinol.31 (1): 13–26. (March 2006). PMID16498361.
“Cyclooxygenase‐2, Prostaglandin E2, and Microglial Activation in Prion Diseases”. Cyclooxygenase-2, prostaglandin E2, and microglial activation in prion diseases. International Review of Neurobiology. 82. (2007). 265–75. doi:10.1016/S0074-7742(07)82014-9. ISBN9780123739896. PMID17678966